HEICO Corp. 10-Q Summary: Quarter Ended January 31, 1995
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended January 31, 1995. HEICO Corporation operates through two primary segments: HEICO Aerospace Corporation (commercial jet engine replacement parts) and MediTek Health Corporation (medical diagnostic services). The company reported 2,279,896 shares of common stock outstanding as of February 28, 1995.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Sales | $8,933,000 | $6,909,000 |
| Net Income | $569,000 | $500,000 |
| Diluted EPS | $0.25 | $0.21 |
| Operating Income | $909,000 | $110,000 |
| Cash from Operations | $714,000 | $462,000 |
| Total Debt (Current + Long-term) | $8,723,000 | $5,456,000 |
| Cash and Equivalents | $3,497,000 | $5,030,000 |
| Working Capital | $12,540,000 | $12,691,000 |
Note: Q1 1994 Net Income included a one-time $381,000 gain from a change in accounting for income taxes. Excluding this, Q1 1995 net income increased 378% over the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 29% year-over-year, driven by a 44% increase in MediTek sales ($3.54M vs $2.45M) and a 21% increase in Aerospace sales ($5.39M vs $4.46M).
- Margin Expansion: MediTek gross margins improved to 34.5% from 28.9%, and Aerospace margins rose to 32.3% from 24.7%, attributed to new high-margin centers and product mix shifts.
- Debt Increase: Total debt rose significantly due to financing for new MediTek centers. Interest expense doubled to $92,000 from $42,000.
- Backlog: Aerospace backlog stood at $13.3 million, up $2.7 million from the prior year but down $1 million from the previous quarter due to increased shipments.
Outlook, Risks, and Contingencies
Management Commentary: Management attributes improved earnings to volume growth in aerospace parts and the inclusion of new medical diagnostic facilities. SG&A expenses as a percentage of sales declined to 21.0% from 22.9% despite absolute dollar increases.
Legal Contingency (Florida Fee Caps): A significant risk involves Florida state legislation capping fees for diagnostic imaging. A state court ruled these caps unconstitutional in February 1995, but the State is expected to appeal. If reinstated, the caps could materially adversely impact MediTek, which generated approximately 47% of its operating income from Florida operations in this quarter.
Unusual Items: The prior year's results included a $381,000 cumulative effect of a change in accounting for income taxes, which is not present in the current period.
Investor Verification Checklist
- Verify the status of the Florida State Court appeal regarding diagnostic imaging fee caps and potential retroactive application.
- Confirm the sustainability of the improved gross margins in both Aerospace and MediTek segments.
- Review the composition of the $13.3 million Aerospace backlog, noting that approximately $6 million is based on estimated customer quantities.
- Assess the impact of rising interest expenses on future profitability given the increased debt load for MediTek expansion.